A NEW STUDY FORPeople With Metastatic Colon or Rectal Cancer
About STELLAR-303
STELLAR-303 is a to see if two study drugs
(XL092 and atezolizumab) work when used together to treat that continued to grow or spread after other treatments.
Clinical trials help researchers and doctors learn more about medical conditions. Studies like this one help researchers understand whether a study drug is safe and if it works to treat a certain disease or condition. Keep reading to learn more about this study.
Contact Us
Call 1-888-393-5494 (toll-free) or 1-303-389-1847, or email medinfo@exelixis.com to learn more about this study.
THE COMBINATION OF XL092 AND ATEZOLIZUMAB HAS NOT BEEN APPROVED BY THE FDA. THE SAFETY AND EFFECTIVENESS OF THIS STUDY TREATMENT HAVE NOT BEEN ESTABLISHED AND ARE BEING STUDIED AS PART OF THIS CLINICAL TRIAL.
Who Can Join the STELLAR‑303 Clinical Trial?
Each clinical trial clearly states who can or cannot join; this is called the eligibility criteria. You may be eligible for STELLAR-303 if:
- You are at least 18 years of age
- You have colon or rectal cancer that has spread to other parts of the body (metastatic)
- Your colon or rectal cancer continued to grow or spread after treatment
There are other eligibility requirements you must meet to join the trial. Download the STELLAR-303 Discussion Guide and talk with your doctor.
Talk with your doctor to learn if this study may be an option for you.
Discussion Guide
(Questions for your doctor)
To find out more about joining the STELLAR-303 trial, download the Discussion Guide with questions that will help you talk with your doctor.
Learn More About the Study
People enrolled in STELLAR-303 will be assigned by chance to one of two study treatment groups. Each group will be treated with different study drugs for their metastatic colon or rectal cancer.
Group A
People in this group will get the new investigational treatment being studied: XL092 and atezolizumab.
Group B
People in this control group will get a common treatment for metastatic colon or rectal cancer: regorafenib.
The trial will compare Groups A and B to see whether these study drugs help people with metastatic colon or rectal cancer live longer.
People in the study will be assigned to a treatment group by chance. Each group will be treated with different drugs.
A computer will randomly assign each person to one of the groups:
Group A (investigational group) will get XL092 and atezolizumab
Group B (control group) will get regorafenib
Frequently Asked Questions
If this is the first time you are thinking of taking part in a clinical trial, you may have questions. Our FAQs may help answer them.
ClinicalTrials.gov
Additional details about STELLAR-303 can be found at ClinicalTrials.gov by searching for NCT05425940.
Is There a Clinical Study Site Near Me?
STELLAR-303 will take place in the U.S. and abroad. For specific location and site information, and to confirm whether sites near you are still enrolling new participants, call 1-888-393-5494 (toll-free) or 1-303-389-1847, or email medinfo@exelixis.com.
Currently open or planned clinical site cities:
Trial sites may stop enrolling participants at any time. Please check back if you do not see a trial site located near you.
Resources
The following sites can provide information and resources for people living with metastatic colon and rectal cancer. They provide educational materials, including webinars and patient guides, and information about support groups.
Cancer.net
Information from the American Society of Clinical Oncology (ASCO) for people living with cancer, as well as for their families and caregivers.
NCCN Guidelines for Patients®
The National Comprehensive Cancer Network® (NCCN®) provides free patient guidelines to help people with cancer talk with their physicians about the best treatment options for their disease.*
Colorectal Cancer Alliance
The Colorectal Cancer Alliance advocates for prevention, magnifies support, and accelerates research to end this disease. Connect with certified patient navigators at 1-877-422-2030.
THE COMBINATION OF XL092 AND ATEZOLIZUMAB HAS NOT BEEN APPROVED BY THE FDA. THE SAFETY AND EFFECTIVENESS OF THIS STUDY TREATMENT HAVE NOT BEEN ESTABLISHED AND ARE BEING STUDIED AS PART OF THIS CLINICAL TRIAL.